Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

Graph AI, a California-based AI life sciences company focused on patient safety and pharmacovigilance, has raised $3 million in a seed funding round led by Bessemer Venture Partners. The investment will help the company accelerate product innovation, expand its engineering team, and drive global adoption of its AI-native solutions.

 

“We’re excited to partner with Graph AI as they redefine labour-intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritise both accuracy and scalability,” said Nithin Kaimal, partner and chief operating officer at Bessemer Venture Partners India.

 

AI-led disruption in the $8 billion pharmacovigilance market 

Graph AI represents a new generation of AI-native challengers transforming the $8 billion pharmacovigilance market. Pharmacovigilance, mandated by drug regulators worldwide, requires pharmaceutical companies to monitor, detect, and report adverse drug events (ADEs) throughout a drug’s lifecycle — from clinical trials to post-market use — ensuring patient safety and regulatory compliance.

 

 

Traditionally, pharmaceutical companies have relied on large service firms that manually process vast amounts of unstructured data, including call centre transcripts, legal filings, medical literature, emails, and social media posts. These manual workflows are labour-intensive, fragmented, and reactive, leading to operational inefficiencies and delays in regulatory reporting and compliance.

 

Founders with deep tech and pharma expertise 

Founded in 2024, Graph AI is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO) — industry veterans with experience at LTI Mindtree, Infosys, ServiceNow, Google, and Cisco. Their expertise in technology, outsourcing, and enterprise operations has shaped Graph’s vision of transforming pharmacovigilance through AI-driven innovation.

 

“Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical and biotech enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations,” the founders said in a joint statement.

 

Strong growth and early traction in enterprise adoption 

Within a year of its founding, Graph AI has reported strong traction, with enterprise clients achieving up to 70 per cent efficiency gains, 90 per cent faster regulatory reporting, and significant cost savings, while maintaining full traceability and audit readiness.

 

The company’s AI-driven platform now supports over 7,000 marketed drugs, reflecting growing enterprise demand and the expanding scope of pharmacovigilance modernisation.

 

Generative AI powering automation and compliance 

Graph AI has built an in-house generative AI studio that streamlines every stage of content and data processing — from ideation and scripting to regulatory report generation and sentiment analysis. Its tools are also used for multilingual translation, ad creation, and predictive analytics, significantly reducing manual workloads and turnaround times.

 

“Graph AI’s focus on data-driven automation is reshaping how life sciences firms ensure safety and compliance,” Kaimal added, underscoring investor confidence in the company’s ability to scale globally.